Latest Breaking News On - Cellectis the company euronext growth - Page 1 : comparemela.com

Cellectis S A : Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications 12 Jun 2024 22:30 CEST .

France generalNorth carolinaUnited statesNew yorkAshleyr robinsonPascalyne wilsonCellecti pulseagilePatricia sosa navarroArthur strilJulien valtonCellectis the company euronext growthSecurities exchange commissionNature communicationsEuronext growthVice president gene therapyAdult hemoglobin

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France generalNew yorkUnited statesNorth carolinaPascalyne wilsonCellecti pulseagileJulien valtonPatricia sosa navarroArthur strilAshleyr robinsonSecurities exchange commissionNature communicationsCellectis the company euronext growthNon viral gene therapy approachSickle cell diseaseEuronext growth

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell

France generalNew yorkUnited statesNorth carolinaJulien valtonPascalyne wilsonArthur strilCellecti pulseagileAshleyr robinsonPatricia sosa navarroCellectis the company euronext growthSecurities exchange commissionNature communicationsEuronext growthVice president gene therapyAdult hemoglobin

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaNew yorkFrance generalAshleyr robinsonArthur strilMark frattiniPascalyne wilsonPatricia sosa navarroAmerican society of hematologyCellectis the company euronext growthEuropean medicines agencyEuropean unionSecurities exchange commissionCommittee for orphan medicinal productsEuropean commission

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell

United statesNorth carolinaFrance generalNew yorkPatricia sosa navarroPascalyne wilsonMark frattiniAshleyr robinsonArthur strilEuropean medicines agencyCellectis the company euronext growthAmerican society of hematologyEuropean commissionSecurities exchange commissionEuropean unionCommittee for orphan medicinal products